CoQ10 Fails to Deliver a Performance Edge for Athletes, Major Meta-Analysis Finds

Coenzyme Q10 has long occupied a privileged place on the shelves of sports nutrition, marketed as the mitochondrial molecule that lets athletes train harder, recover faster, and race stronger. Now one of the most rigorous assessments of the supplement to date has delivered a sobering verdict. A systematic review and meta-analysis published in the journal 3 Biotech by Shanshan Lu of Huaibei Normal University, Wen Zhong of Beijing Sport University, and Hongyi Wang of Zhengzhou University concludes that the current evidence does not support a robust overall ergogenic or physiological benefit of oral CoQ10 supplementation in athletes. The finding strikes at the heart of a supplement industry built on the promise of cellular energy, and it arrives with a methodological weight that will be difficult to dismiss.

The logic behind CoQ10 supplementation is seductively straightforward. The molecule is an essential cofactor in the mitochondrial electron transport chain, shuttling electrons between complexes I and III during oxidative phosphorylation, the process that generates the bulk of cellular ATP. It also functions as a powerful lipid-phase antioxidant, quenching the free radicals that attack cell membranes. Because strenuous exercise dramatically increases oxygen flux through working muscles, it simultaneously increases the production of reactive oxygen species. Exercise-induced oxidative stress has been proposed as a mechanistic link between heavy training loads, membrane injury, impaired recovery, and inconsistent performance responses. Supplementing with the antioxidant cofactor that sits at the crossroads of energy production and radical defense therefore seemed like an obvious win for athletes, even as individual randomized trials kept returning contradictory results.

To resolve that contradiction, the Chinese research team conducted a prospectively registered systematic review, searching PubMed, Web of Science, Embase, and EBSCOhost from database inception to April 2026, with the protocol registered in PROSPERO under identifier CRD420261370320. They included randomized parallel-group and crossover trials evaluating oral CoQ10 in athletes or athlete-relevant trained individuals. The final tally was twenty-four studies encompassing 613 participants for the systematic review, with fifteen studies and 330 participants contributing to at least one quantitative synthesis. Because several studies contributed more than one eligible estimate, the unit of quantitative reporting was the effect size or comparison, and random-effects models were used throughout the meta-analysis.

The headline result concerns malondialdehyde, or MDA, a widely used biomarker of lipid peroxidation that serves as a chemical fingerprint of oxidative damage to cell membranes. The primary pooled analysis for MDA included seven effect sizes drawn from five studies and was not statistically significant, with a standardized mean difference of negative 0.96 and a 95 percent confidence interval spanning from negative 2.07 to positive 0.15. In other words, the point estimate suggested a substantial reduction in oxidative damage, but the uncertainty was so wide that the result could not be distinguished from chance. A sensitivity analysis tightened the interval to negative 0.93 with a confidence interval of negative 1.65 to negative 0.22, favoring CoQ10, yet the authors emphasize that this signal remained fragile, burdened by residual heterogeneity with an I-squared statistic of 73 percent, small sample sizes, and methodological limitations in the underlying trials.

The physiological picture was even more definitive. The representative pooled performance outcome, maximal oxygen uptake or VO2max, included eight effect sizes from seven studies and was essentially neutral, with a standardized mean difference of 0.03 and a confidence interval of negative 0.32 to positive 0.39. The I-squared statistic of 0.0 percent indicates remarkable consistency across trials, but the consistency points to a null effect rather than a benefit. Supplementary pooled analyses were likewise neutral for blood pressure, creatine kinase, interleukin-6, total antioxidant capacity, tumor necrosis factor-alpha, and anaerobic threshold. For a supplement whose promotional materials promise everything from faster recovery to enhanced endurance capacity, the absence of any measurable effect on inflammation, muscle damage, cardiovascular parameters, or aerobic fitness represents a comprehensive null result.

Perhaps the most damning statistic in the entire analysis concerns the quality of the evidence itself. Using the revised Cochrane risk-of-bias tool, the authors judged overall risk of bias as raising some concerns in twenty-three of the twenty-four included studies, or 95.8 percent, with one study judged at high risk, or 4.2 percent. Not a single trial emerged unscathed. This matters because biased trials tend to inflate effect estimates, which means the modest signals that did emerge may themselves be overestimates. The finding echoes a persistent problem in sports nutrition research, where small samples, short durations, and commercial entanglements frequently undermine the reliability of individual studies, leaving meta-analysts to extract signal from noise.

There is, however, a nuanced thread running through the narrative synthesis. The authors observed more coherent, context-dependent signals in studies conducted under conditions of marked oxidative or recovery stress, such as elite swimmers combining supplementation with pre-cooling strategies, or athletes undergoing intensive training camps. This pattern fits with a broader understanding of exercise physiology: reactive oxygen species are not simply damaging byproducts but also serve as signaling molecules that trigger adaptive responses, including endogenous antioxidant enzyme upregulation and mitochondrial biogenesis. Blunting oxidative stress indiscriminately during moderate training might even interfere with adaptation, whereas athletes under extreme oxidative loads could plausibly benefit from additional antioxidant capacity. The review cannot confirm this hypothesis, but it offers a framework for designing better-targeted future trials.

The biochemistry of CoQ10 also helps explain why results have been so inconsistent. The molecule is highly lipophilic and poorly absorbed, and plasma response to oral ingestion varies substantially between formulations, with ubiquinol, the reduced form, generally achieving higher circulating concentrations than ubiquinone. Studies have shown that supplementation does reliably enrich plasma and blood cells, yet raising blood levels does not guarantee that the coenzyme reaches the mitochondria of working muscle in sufficient quantities to alter electron transport flux or membrane protection. A recent companion study cited in the review found that CoQ10 supplementation raised plasma levels without improving mitochondrial function in older adults, underscoring the gap between what blood tests measure and what muscle cells actually experience.

For the global supplement market, where CoQ10 products are frequently marketed to endurance athletes and fitness enthusiasts, the implications are uncomfortable. The new analysis aligns with earlier systematic reviews, including a 2024 GRADE-assessed dose-response meta-analysis and a 2025 review in the British Journal of Nutrition that found limited and inconsistent effects on exercise performance despite reliable increases in blood concentrations. The consistent pattern across independent teams, databases, and decades of trials, stretching back to studies of trained cyclists and cross-country skiers in the 1990s, suggests that the null findings are not an artifact of any single analysis but a genuine property of the intervention in healthy, well-trained populations.

The authors stop short of declaring CoQ10 useless, and their caution is warranted. The potentially favorable MDA signal in the sensitivity analysis, the hints of benefit under extreme oxidative stress, and the heterogeneity of study designs all leave room for refined hypotheses, perhaps involving specific populations, dosing regimens, or combinations with other interventions. But for the average athlete contemplating a daily capsule in pursuit of a competitive edge, the message from this comprehensive synthesis is clear: the best available evidence shows no meaningful improvement in aerobic capacity, muscle damage markers, inflammation, blood pressure, or antioxidant status. Until higher-quality trials demonstrate otherwise, the molecule that powers mitochondria appears unable to power personal bests.

Subject of Research: Effects of coenzyme Q10 supplementation on exercise-induced oxidative stress and physiological outcomes in athletes

Article Title: The effects of coenzyme Q10 supplementation on exercise-induced oxidative stress and related physiological outcomes in athletes: a systematic review and meta-analysis

Article References: Lu, S., Zhong, W., & Wang, H. (2026). The effects of coenzyme Q10 supplementation on exercise-induced oxidative stress and related physiological outcomes in athletes: a systematic review and meta-analysis. 3 Biotech, 16(10), Article 445. https://doi.org/10.1007/s13205-026-05076-4

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05076-4

Keywords: coenzyme Q10, athletes, oxidative stress, malondialdehyde, VO2max, meta-analysis, systematic review, sports nutrition, mitochondria, exercise physiology, dietary supplements, recovery